questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines du sang
Immunoprotéines
Protéines du système du complément
Complément C3
Complément C3b
Complément C3c
Complément C3c : Questions médicales fréquentes
Termes MeSH sélectionnés :
Neovascularization, Pathologic
Diagnostic
5
Compléments
Tests de laboratoire
Compléments
Tests de laboratoire
Maladies auto-immunes
Inflammation
Marqueurs biologiques
Pathologies
Système du complément
Diagnostic
Symptômes
5
Système immunitaire
Symptômes
Prévention
5
Prévention
Maladies chroniques
Vaccins
Système immunitaire
Stress
Système immunitaire
Examens médicaux
Prévention
Traitements
5
Immunothérapie
Traitement
Médicaments immunosuppresseurs
Compléments
Suivi médical
Compléments
Alimentation
Système immunitaire
Transfusions sanguines
Compléments
Complications
5
Infections
Maladies auto-immunes
Complications
Inflammation
Maladies cardiovasculaires
Risques
Facteurs de risque
5
Facteurs de risque
Maladies auto-immunes
Antécédents familiaux
Maladies immunitaires
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Complément C3c : Questions médicales les plus fréquentes",
"headline": "Complément C3c : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Complément C3c : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-04",
"dateModified": "2025-03-31",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Complément C3c"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Complément C3b",
"url": "https://questionsmedicales.fr/mesh/D003179",
"about": {
"@type": "MedicalCondition",
"name": "Complément C3b",
"code": {
"@type": "MedicalCode",
"code": "D003179",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.250.260"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Complément C3c",
"alternateName": "Complement C3c",
"code": {
"@type": "MedicalCode",
"code": "D015932",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Marinos C Dalakas",
"url": "https://questionsmedicales.fr/author/Marinos%20C%20Dalakas",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA. mdalakas@med.uoa.gr."
}
},
{
"@type": "Person",
"name": "Shruti Chaturvedi",
"url": "https://questionsmedicales.fr/author/Shruti%20Chaturvedi",
"affiliation": {
"@type": "Organization",
"name": "Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA."
}
},
{
"@type": "Person",
"name": "Robert A Brodsky",
"url": "https://questionsmedicales.fr/author/Robert%20A%20Brodsky",
"affiliation": {
"@type": "Organization",
"name": "Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA."
}
},
{
"@type": "Person",
"name": "Keith R McCrae",
"url": "https://questionsmedicales.fr/author/Keith%20R%20McCrae",
"affiliation": {
"@type": "Organization",
"name": "Division of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH."
}
},
{
"@type": "Person",
"name": "Martin Kohn",
"url": "https://questionsmedicales.fr/author/Martin%20Kohn",
"affiliation": {
"@type": "Organization",
"name": "Institute of Medical Microbiology and Hospital Epidemiology, Medical School Hannover, Hannover, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Harnessing retinal phagocytes to combat pathological neovascularization in ischemic retinopathies?",
"datePublished": "2022-05-07",
"url": "https://questionsmedicales.fr/article/35524802",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00424-022-02695-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Downregulation of PIK3IP1 in retinal microglia promotes retinal pathological neovascularization via PI3K-AKT pathway activation.",
"datePublished": "2023-08-07",
"url": "https://questionsmedicales.fr/article/37550343",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-39473-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Novel theranostic approaches to neovascularized atherosclerotic plaques.",
"datePublished": "2023-05-02",
"url": "https://questionsmedicales.fr/article/37149970",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.atherosclerosis.2023.04.008"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hyperacute iris neovascularization following cataract surgery.",
"datePublished": "2022-07-08",
"url": "https://questionsmedicales.fr/article/35801772",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MD.0000000000029356"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hyperreflective material in patients with non-neovascular pachychoroid disease.",
"datePublished": "2023-06-06",
"url": "https://questionsmedicales.fr/article/37280611",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12886-023-03011-2"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines du sang",
"item": "https://questionsmedicales.fr/mesh/D001798"
},
{
"@type": "ListItem",
"position": 5,
"name": "Immunoprotéines",
"item": "https://questionsmedicales.fr/mesh/D007162"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines du système du complément",
"item": "https://questionsmedicales.fr/mesh/D003165"
},
{
"@type": "ListItem",
"position": 7,
"name": "Complément C3",
"item": "https://questionsmedicales.fr/mesh/D003176"
},
{
"@type": "ListItem",
"position": 8,
"name": "Complément C3b",
"item": "https://questionsmedicales.fr/mesh/D003179"
},
{
"@type": "ListItem",
"position": 9,
"name": "Complément C3c",
"item": "https://questionsmedicales.fr/mesh/D015932"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Complément C3c - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Complément C3c",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Complément C3c",
"description": "Comment mesurer le complément C3c ?\nQuels tests sont associés au C3c ?\nQuand évaluer le C3c ?\nLe C3c est-il un marqueur de maladie ?\nQuel rôle joue le C3c dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D015932?mesh_terms=Neovascularization,+Pathologic#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Complément C3c",
"description": "Quels symptômes sont liés à un faible C3c ?\nUn C3c élevé indique-t-il des symptômes ?\nLe C3c affecte-t-il la fatigue ?\nY a-t-il des symptômes spécifiques au C3c ?\nLe C3c est-il lié à des douleurs ?",
"url": "https://questionsmedicales.fr/mesh/D015932?mesh_terms=Neovascularization,+Pathologic#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Complément C3c",
"description": "Comment prévenir les anomalies du C3c ?\nLe vaccin influence-t-il le C3c ?\nY a-t-il des habitudes à éviter ?\nLe stress affecte-t-il le C3c ?\nDes examens réguliers sont-ils nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D015932?mesh_terms=Neovascularization,+Pathologic#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Complément C3c",
"description": "Comment traiter un faible C3c ?\nDes médicaments affectent-ils le C3c ?\nLe C3c nécessite-t-il un suivi ?\nPeut-on augmenter le C3c naturellement ?\nLes transfusions affectent-elles le C3c ?",
"url": "https://questionsmedicales.fr/mesh/D015932?mesh_terms=Neovascularization,+Pathologic#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Complément C3c",
"description": "Quelles complications peuvent survenir avec un C3c bas ?\nUn C3c élevé cause-t-il des complications ?\nLe C3c affecte-t-il la guérison des blessures ?\nY a-t-il des risques de thrombose liés au C3c ?\nLe C3c influence-t-il les maladies cardiovasculaires ?",
"url": "https://questionsmedicales.fr/mesh/D015932?mesh_terms=Neovascularization,+Pathologic#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Complément C3c",
"description": "Quels facteurs augmentent le risque de C3c anormal ?\nL'âge influence-t-il le C3c ?\nLe sexe joue-t-il un rôle dans le C3c ?\nLe mode de vie affecte-t-il le C3c ?\nLes antécédents familiaux influencent-ils le C3c ?",
"url": "https://questionsmedicales.fr/mesh/D015932?mesh_terms=Neovascularization,+Pathologic#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment mesurer le complément C3c ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le complément C3c est mesuré par un test sanguin spécifique en laboratoire."
}
},
{
"@type": "Question",
"name": "Quels tests sont associés au C3c ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de C3c sont souvent associés à des dosages de C3 et C4."
}
},
{
"@type": "Question",
"name": "Quand évaluer le C3c ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le C3c est évalué lors de suspicion de maladies auto-immunes ou inflammatoires."
}
},
{
"@type": "Question",
"name": "Le C3c est-il un marqueur de maladie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux de C3c peuvent indiquer des pathologies sous-jacentes."
}
},
{
"@type": "Question",
"name": "Quel rôle joue le C3c dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le C3c aide à évaluer l'activité du système du complément dans diverses conditions."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à un faible C3c ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un faible C3c peut entraîner des infections fréquentes et des inflammations."
}
},
{
"@type": "Question",
"name": "Un C3c élevé indique-t-il des symptômes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un C3c élevé peut être associé à des symptômes d'inflammation ou d'infection."
}
},
{
"@type": "Question",
"name": "Le C3c affecte-t-il la fatigue ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux de C3c peuvent contribuer à la fatigue liée à l'inflammation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques au C3c ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, le C3c n'a pas de symptômes spécifiques, mais reflète l'état immunitaire."
}
},
{
"@type": "Question",
"name": "Le C3c est-il lié à des douleurs ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de C3c peuvent être associés à des douleurs inflammatoires."
}
},
{
"@type": "Question",
"name": "Comment prévenir les anomalies du C3c ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un mode de vie sain et gérer les maladies chroniques aide à prévenir les anomalies."
}
},
{
"@type": "Question",
"name": "Le vaccin influence-t-il le C3c ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccins peuvent stimuler le système immunitaire, influençant potentiellement le C3c."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes à éviter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabagisme et une mauvaise alimentation peut aider à maintenir un C3c normal."
}
},
{
"@type": "Question",
"name": "Le stress affecte-t-il le C3c ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut perturber le système immunitaire et affecter le C3c."
}
},
{
"@type": "Question",
"name": "Des examens réguliers sont-ils nécessaires ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent aider à détecter des anomalies du C3c tôt."
}
},
{
"@type": "Question",
"name": "Comment traiter un faible C3c ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement dépend de la cause sous-jacente, souvent par immunothérapie."
}
},
{
"@type": "Question",
"name": "Des médicaments affectent-ils le C3c ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments immunosuppresseurs peuvent réduire les niveaux de C3c."
}
},
{
"@type": "Question",
"name": "Le C3c nécessite-t-il un suivi ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est recommandé pour surveiller les niveaux de C3c."
}
},
{
"@type": "Question",
"name": "Peut-on augmenter le C3c naturellement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et un mode de vie sain peuvent soutenir le système immunitaire."
}
},
{
"@type": "Question",
"name": "Les transfusions affectent-elles le C3c ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les transfusions peuvent influencer les niveaux de C3c en fonction des composants."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec un C3c bas ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un C3c bas peut entraîner des infections récurrentes et des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Un C3c élevé cause-t-il des complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un C3c élevé peut être lié à des complications inflammatoires et des maladies chroniques."
}
},
{
"@type": "Question",
"name": "Le C3c affecte-t-il la guérison des blessures ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux de C3c peuvent retarder la guérison en perturbant l'inflammation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de thrombose liés au C3c ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de C3c peuvent être associés à un risque accru de thrombose."
}
},
{
"@type": "Question",
"name": "Le C3c influence-t-il les maladies cardiovasculaires ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux de C3c peuvent être liés à un risque accru de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de C3c anormal ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les maladies auto-immunes, infections chroniques et certains médicaments augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le C3c ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge peut affecter les niveaux de C3c, souvent en raison de changements immunitaires."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le C3c ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des différences hormonales peuvent influencer les niveaux de C3c entre les sexes."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le C3c ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent affecter le C3c."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le C3c ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies immunitaires peuvent augmenter le risque de C3c anormal."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 31/03/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA. mdalakas@med.uoa.gr.
Neuroimmunology Unit, Department of Pathophysiology, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece. mdalakas@med.uoa.gr.
Publications dans "Complément C3c" :
4 publications dans cette catégorie
Affiliations :
Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Publications dans "Complément C3c" :
4 publications dans cette catégorie
Affiliations :
Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Publications dans "Complément C3c" :
3 publications dans cette catégorie
Affiliations :
Division of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
Publications dans "Complément C3c" :
2 publications dans cette catégorie
Affiliations :
Institute of Medical Microbiology and Hospital Epidemiology, Medical School Hannover, Hannover, Germany.
Publications dans "Complément C3c" :
2 publications dans cette catégorie
Affiliations :
Institute of Medical Microbiology and Hospital Epidemiology, Medical School Hannover, Hannover, Germany.
Publications dans "Complément C3c" :
2 publications dans cette catégorie
Affiliations :
Institute of Medical Microbiology and Hospital Epidemiology, Medical School Hannover, Hannover, Germany.
Publications dans "Complément C3c" :
2 publications dans cette catégorie
Affiliations :
Institute for Laboratory Animal Science, Medical School Hannover, Hannover, Germany.
Publications dans "Complément C3c" :
2 publications dans cette catégorie
Affiliations :
Institute of Medical Microbiology and Hospital Epidemiology, Medical School Hannover, Hannover, Germany.
Publications dans "Complément C3c" :
2 publications dans cette catégorie
Affiliations :
Institute of Medical Microbiology and Hospital Epidemiology, Medical School Hannover, Hannover, Germany.
Publications dans "Complément C3c" :
2 publications dans cette catégorie
Publications dans "Complément C3c" :
2 publications dans cette catégorie
Affiliations :
Department of Biomedicine, Aarhus University, Aarhus C, Denmark.
Publications dans "Complément C3c" :
2 publications dans cette catégorie
Affiliations :
Translational Bio-Nanosciences Laboratory, Department of Pharmaceutical Sciences, Skaggs School of Pharmacy, University of Colorado Anschutz Medical Center, Aurora, CO, USA; Colorado Center for Nanomedicine and Nanosafety, University of Colorado Anschutz Medical Center, Aurora, CO, USA.
Publications dans "Complément C3c" :
2 publications dans cette catégorie
Affiliations :
Radboud Institute for Molecular Life Sciences, Department of Pediatric Nephrology, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, Netherlands.
Publications dans "Complément C3c" :
2 publications dans cette catégorie
Affiliations :
Department of Immunology, University of Oslo and Oslo University Hospital Rikshospitalet, Oslo, Norway.
Linnaeus Centre for Biomaterials Chemistry, Linnaeus University, Kalmar, Sweden.
Department of Chemistry and Biomedical Sciences, Linnaeus University, Kalmar, Sweden.
Publications dans "Complément C3c" :
2 publications dans cette catégorie
Affiliations :
Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Publications dans "Complément C3c" :
2 publications dans cette catégorie
Affiliations :
BMT Unit, Hematology Department, G. Papanicolaou Hospital, Thessaloniki, Greece.
Publications dans "Complément C3c" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, United States.
Publications dans "Complément C3c" :
2 publications dans cette catégorie
Affiliations :
Centre de Recherche des Cordeliers, Inserm UMR S1138, Paris, France.
Department of Nephrology Dialysis and Transplantation, University Hospital of Strasbourg, Strasbourg, France.
Publications dans "Complément C3c" :
2 publications dans cette catégorie
Affiliations :
Centre de Recherche des Cordeliers, Inserm UMR S1138, Paris, France.
Service d'Immunologie, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.
Publications dans "Complément C3c" :
Ischemic retinopathies (IR) are vision-threatening diseases that affect a substantial amount of people across all age groups worldwide. The current treatment options of photocoagulation and anti-VEGF ...
Retinal pathological neovascularization involves endothelial cells, pericytes, photoreceptor cells, ganglion cells, and glial cells, whose roles remain unclear. Using the Scissor algorithm, we found t...
As the global burden of atherosclerotic cardiovascular disease continues to rise, there is an increased demand for improved imaging techniques for earlier detection of atherosclerotic plaques and new ...
We describe a case of acute neovascularization of the iris after uneventful cataract surgery....
A 78-year-old man visited our clinic for cataract surgery and glaucoma management....
The patient underwent bilateral laser iridotomy 4 years ago. On ocular examination, the best-corrected visual acuity was no light perception in the right eye and 20/100 in the left eye. We observed ps...
The patient underwent cataract surgery in the left eye without complications....
The day after surgery we observed 360° of neovascularization in the iris and aggravated hemi-CRVO with macular edema. Therefore, we administered intravitreal bevacizumab in the left eye, after which t...
Cataract surgery can rapidly aggravate hemi-CRVO and cause iris neovascularization, which is responsive to bevacizumab....
This study aimed to report eleven cases of non-neovascular pachychoroid disease with hyperreflective material (HRM) that occurred in Japanese patients....
A retrospective review of data from eleven patients who had non-neovascular retinal pigment epithelium (RPE) protrusion with HRM in the neurosensory retina between March 2017 and June 2022 was conduct...
All cases had RPE protrusion and HRM with dilated choroidal veins, which were characteristic of pachychoroid disease. However, none of the cases had macular neovascularization (MNV). In 9 eyes (81.8%)...
There are some cases of non-neovascular pachychoroid disorder with HRM, which might be a new entity of pachychoroid spectrum disease or an early stage of PPE or FCE. These cases should not be misdiagn...
We evaluated 1-year outcomes of loading phase treatment followed by maintenance treatment using a treat-and-extend (TAE) regimen with intravitreal brolucizumab for neovascular age-related macular dege...
We previously reported one-year results of a treat-and-extend (TAE) regimen with intravitreal brolucizumab for 68 eyes with treatment-naïve neovascular age-related macular degeneration (nAMD) associat...
Diabetic retinopathy (DR) is a common complication of diabetes, and recent findings have shown that long noncoding RNAs (lncRNAs) may be involved in its pathogenesis. Through bioinformatics analysis, ...
We used RT‒PCR to assess the expression levels of lncRNA ATP2B2-IT2 and vascular endothelial growth factor (VEGF) in HRMECs under normal glucose (5.5 mmol/L) and high glucose (30 mmol/L) conditions. H...
RT‒PCR revealed that the expression levels of the lncRNA ATP2B2-IT2 and VEGF were greater in the HG group than in the NG group (P < 0.05). After silencing of the lncRNA ATP2B2-IT2, the expression of V...
LncRNA ATP2B2-IT2 may promote the proliferation, migration and neovascularization of HRMECs under high-glucose conditions....
To report the cumulative incidence and risk factors of second eye involvement after diagnosis of myopic macular neovascularization (MNV) in the first eye....
Retrospective analysis of longitudinal data from a tertiary hospital in the Netherlands....
Patients with high myopia (spherical equivalent [SE] ≤ - 6 diopters [D]), of European ethnicity, who were diagnosed with active MNV lesion in 1 eye between 2005 and 2018. Fellow eyes were free of MNV ...
Incidence rate and 2-, 5-, and 10-year cumulative incidences were calculated; hazard ratios (HRs) of second eye involvement were analyzed for potential risk factors using Cox proportional hazard model...
Incidence of second eye involvement after onset of myopic MNV in the first eye....
We included 88 patients over a period of 13 years with a mean age of 58 ± 15 years, mean axial length of 30 ± 1.7 mm and SE -14 ± 4 D at baseline. Twenty-four fellow eyes (27%) developed a myopic MNV ...
Our study of high myopes of European descent shows very similar incidence rates for second eye myopic MNV compared with Asian studies. Our findings substantiate the importance for clinicians to monito...
The authors have no proprietary or commercial interest in any materials discussed in this article....
To examine the role of CCL14 in the neovascularization process and vulnerability progression within carotid plaques by investigating the mechanism of CCL14 regulation of VEGF-A....
We first performed histological analysis and immunohistochemical staining of human carotid plaque tissue to detect the expression of CCL14, JAK2, STAT3 and VEGF-A. We next examined the protein express...
Histological and Western blotting analysis of human carotid plaque samples showed that the expression of CCL14 and VEGF-A was higher in the vulnerable plaques than in stable plaques. In the in vitro c...
In the human carotid plaques, CCL14 promotes angiogenesis by upregulation of VEGF-A via JAK2/STAT3 pathway and thus drives the progression of carotid plaques vulnerability....